Altimmune, Inc. (ALT) Form 8-K — May 13, 2026
Altimmune, Inc. (Nasdaq: ALT) announced its financial results for the first quarter ended March 31, 2026. The company reported a net loss of $22.6 million, or $0.18 per share, compared to a net loss of $19.6 million, or $0.26 per share, in the same period in 2025. The company's cash position as of March 31, 2026, was $332 million, and as of April 30, 2026, it increased to $535 million, reflecting the net proceeds from a $225 million oversubscribed public offering in April 2026.
Key figures
- Eps
- -0.18
- Eps Beat
- 0
- Revenue
- 0
- Net Income
- -22,563
- Total Debt
- 34,505
- Debt Amount
- 0
- Revenue Yoy
- -5
- Total Assets
- 335,630
- Cash Position
- 535,000
- Deal Value Usd
- 0
- Interest Rate
- 0
- Gross Proceeds
- 0
- Offering Price
- 0
- Shares Offered
- 0
- Shares Outstanding
- 130,221,154
- Cash Yoy
- 356,828
- G&A expenses
- 8,052
- R&D expenses
- 16,192
- Interest income
- 2,901
Price after filing
Close on the filing date to close N calendar days later (from $3.02). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.